Journal ArticleDOI
EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer.
Eugene Tulchinsky,Eugene Tulchinsky,Oleg N. Demidov,Marina Kriajevska,Nickolai A. Barlev,Evgeny Imyanitov +5 more
Reads0
Chats0
TLDR
It is proposed that therapeutic inhibition of EMT-activated mechanisms of cell survival in NSCLC would eliminate pools of persister cells and prevent or delay cancer recurrence when applied in combination with the agents targeting EGFR.About:
This article is published in Biochimica et Biophysica Acta.The article was published on 2019-01-01. It has received 127 citations till now. The article focuses on the topics: Epithelial–mesenchymal transition & Targeted therapy.read more
Citations
More filters
The epigenetics of epithelial-mesenchymal plasticity in cancer
Wai Leong Tam,Robert A. Weinberg +1 more
TL;DR: In this article, a review of the interactions between EMT-inducing transcription factors and epigenetic modulators during cancer progression and the therapeutic implications of exploiting this intricate regulatory process is presented.
Journal ArticleDOI
Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
Yuanyuan Jiang,Hanxiang Zhan +1 more
TL;DR: Recent findings on EMT-induced immune suppression and evasion in the tumor microenvironment (TME) and the value of preclinical or clinical trials using EMT targeted therapy combined with PD-L1 inhibitors are investigated.
Journal ArticleDOI
Dynamic EMT: a multi-tool for tumor progression.
TL;DR: The epithelial-mesenchymal transition (EMT) is fundamental for embryonic morphogenesis as discussed by the authors, and it is increasingly understood to orchestrate a large variety of complementary cancer features, such as tumor cell stemness, tumorigenicity, resistance to therapy and adaptation to changes in the microenvironment.
Journal ArticleDOI
Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.
TL;DR: A broad overview of the mechanisms of resistance to targeted therapy that have been demonstrated across molecular subtypes of NSCLC is provided, highlighting the dynamic interplay between driver oncogene, bypass signaling pathways, shifting cellular phenotypes, and surrounding tumor microenvironment.
Journal ArticleDOI
Contribution of Epithelial Plasticity to Therapy Resistance.
TL;DR: The recognition of the presence in tumours of intermediate hybrid epithelial/mesenchymal states as the most likely manifestation of epithelial plasticity and their potential link to stemness and tumour heterogeneity, provide new clues to understanding resistance and could be exploited in the search for anti-resistance strategies.
References
More filters
Journal ArticleDOI
Hallmarks of cancer: the next generation.
TL;DR: Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.
Journal ArticleDOI
A genetic model for colorectal tumorigenesis
Eric R. Fearon,Bert Vogelstein +1 more
TL;DR: A model for the genetic basis of colorectal neoplasia that includes the following salient features is presented, which may be applicable to other common epithelial neoplasms, in which tumors of varying stage are more difficult to study.
Journal ArticleDOI
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
Thomas J. Lynch,Daphne W. Bell,Raffaella Sordella,Sarada Gurubhagavatula,Ross A. Okimoto,Brian W. Brannigan,Patricia L. Harris,Sara M. Haserlat,Jeffrey G. Supko,Frank G. Haluska,David N. Louis,David C. Christiani,Jeff Settleman,Daniel A. Haber +13 more
TL;DR: A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib, and these mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.
Journal ArticleDOI
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more
TL;DR: Results suggest that EGFR mutations may predict sensitivity to gefitinib, and treatment with the EGFR kinase inhibitor gefitsinib causes tumor regression in some patients with NSCLC, more frequently in Japan.
Journal ArticleDOI
Epithelial-Mesenchymal Transitions in Development and Disease
Jean Paul Thiery,Jean Paul Thiery,Hervé Acloque,Ruby Yun-Ju Huang,Ruby Yun-Ju Huang,M. Angela Nieto +5 more
TL;DR: The mesenchymal state is associated with the capacity of cells to migrate to distant organs and maintain stemness, allowing their subsequent differentiation into multiple cell types during development and the initiation of metastasis.